<DOC>
	<DOC>NCT01249027</DOC>
	<brief_summary>This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: - Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use - Evaluate patient compliance to dual antiplatelet therapy (DAPT)</brief_summary>
	<brief_title>XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>The patient or patient's legallyauthorized representative agrees to participate in this study by signing the Ethics Committeeapproved informed consent form (ICF). Only XIENCE V stent(s) is/are implanted into the coronary vasculature during the index procedure. The inability to obtain a signed ICF</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Drug eluting stents</keyword>
	<keyword>Stents</keyword>
	<keyword>China</keyword>
	<keyword>DES</keyword>
	<keyword>XIENCE V EECSS</keyword>
</DOC>